CTLA4 and renal cell carcinoma: Phase III trials of anti-CTLA-4 in melanoma and anti-PD-1 in melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC) showed improved overall survival (OS) compared to standard therapies (1–5).